» Articles » PMID: 35389164

Expression of Mucins in Different Entities of Salivary Gland Cancer: Highest Expression of Mucin-1 in Salivary Duct Carcinoma : Mucin-1 - Highest Expression in Salivary Duct Carcinoma

Overview
Specialties Oncology
Pathology
Date 2022 Apr 7
PMID 35389164
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic options for advanced salivary gland cancer (SGC) are rare. Therefore, it was the aim of this study to investigate the extent and intensity of Mucin-1 (MUC1), Mucin-16 (MUC16), and Mucin-5AC (MUC5AC) as potential molecular targets using immunohistochemistry. The medical records of all patients who underwent primary surgery for salivary gland cancer with curative intent in a tertiary referral center between 1990 and 2018 were reviewed. Immunohistochemical staining for MUC1, MUC16, and MUC5AC was performed for all patients with sufficient formalin-fixed paraffin-embedded material, and a semi-quantitative combined score derived from the H-score for the cytoplasmatic, the membranous and the apical membrane was built for the most common entities of SGC. 107 patients with malignancies of the parotid (89.7%) and the submandibular gland (10.3%) were included. The most common entities were mucoepidermoid carcinoma (MuEp; n = 23), adenoid cystic carcinoma (AdCy; n = 22), and salivary duct carcinoma (SaDu; n = 21). The highest mean MUC1 combined score was found in SaDu with 223.6 (±91.7). The highest mean MUC16 combined score was found in MuEp with 177.0 (±110.0). The mean MUC5AC score was low across all entities. A higher MUC1 combined score was significantly associated with male gender (p = 0.03), lymph node metastasis (p < 0.01), lymphovascular invasion (p = 0.045), and extracapsular extension (p = 0.03). SaDu patients with MUC16 expression showed a significantly worse 5-year progression-free survival than those without MUC16 expression (p = 0.02). This is the first study to give a comprehensive overview of the expression of MUC1, MUC16, and MUC5AC in SGC. Since advanced SGCs lack therapeutic options in many cases, these results warrant in vitro research on therapeutic targets against MUC1 in SaDu cell lines and xenograft models.

Citing Articles

[Clinical and molecular epidemiology of malignant salivary gland tumors].

Jansen L, Nachtsheim L, Mayer M, Arolt C, Quaas A, Klussmann J Laryngorhinootologie. 2024; 104(2):87-93.

PMID: 39419038 PMC: 11790319. DOI: 10.1055/a-2373-5741.


Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.

Mayer M, Nachtsheim L, Prinz J, Shabli S, Suchan M, Klussmann J Clin Exp Metastasis. 2023; 40(5):395-405.

PMID: 37480387 PMC: 10495532. DOI: 10.1007/s10585-023-10222-w.

References
1.
Luna M, BATSAKIS J, Ordonez N, Mackay B, Tortoledo M . Salivary gland adenocarcinomas: a clinicopathologic analysis of three distinctive types. Semin Diagn Pathol. 1987; 4(2):117-35. View

2.
Bauer A, Umer M, Richardson V, Cumpian A, Harder A, Khosravi N . Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight. 2018; 3(15). PMC: 6129115. DOI: 10.1172/jci.insight.120941. View

3.
Arolt C, Hoffmann F, Nachtsheim L, Wolber P, Guntinas-Lichius O, Buettner R . Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. Head Neck Pathol. 2021; 16(2):394-406. PMC: 9187800. DOI: 10.1007/s12105-021-01370-0. View

4.
Galdirs T, Kappler M, Reich W, Eckert A . Current aspects of salivary gland tumors - a systematic review of the literature. GMS Interdiscip Plast Reconstr Surg DGPW. 2019; 8:Doc12. PMC: 6734194. DOI: 10.3205/iprs000138. View

5.
Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S . Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003; 12(4):493-502. View